Entia Biosciences Inc (EM) (ERGO)

is this one coming back to life?

I never said new. It's old management.

Who are the new officers by the way? Which data source are you using?

I am just more selective on OTC plays and yes, I have moved to other plays... Just remember whatever U do, play the chart... charts never lie 99% of the time.. JMO and GLTU

Are you moving away from OTC/PINK and onto NYSE/Nasdaq/AMEX?

Old management won it back. They could have plans for it. Likely selling it themselves.

There seems to be hope once again. Hopefully good news will be issued soon!

I gave up on all of these plays

Is the custodian still in play?

Officers updated.

Sounds bad-are there other options?

AR

AF?

Stipulation is an agreement between two parties, so it looks like AF has decided to terminate the custodian.

Did court go well or not? Trying to understand the lingo.

Is Entia going to ever become valuable under the custodianship? When and how much? I have held this since 2011....

Who's loading the 9s? Set your bid at .15 I'll buy it.

Someone is going to make a lot of money with these cheapies at .0280

This one is cutting it close.

ASK moved to 12 EOD. Normally stays at 9. I'm expecting something soon.

0 ppl talking abt this jfc idiots I swear

ERGO Capital LLC Custodian Play

ERGO Closed strong today

ERGO Case Information

A-21-835782-P | In the Matter of the Petition of Alpharidge Capital LLC
https://www.clarkcountycourts.us/Portal/Case/CaseDetail?eid=kfocv6eFNkqtVcm2YbYbBg2&tabIndex=3

Case Number
A-21-835782-P

Court
Department 29

Judicial Officer
Jones, David M

File Date
06/04/2021

Case Type
Other Civil Filings (Petition)

Case Status
Open

Party
Petitioner
Alpharidge Capital LLC


Active Attorneys

Lead Attorney
Bauman, Frederick C
Retained

Defendant (Participant)
Entia Biosciences Inc.


Events and Hearings

06/04/2021 Application

Comment
Application for the Appointment of Custodian

06/04/2021 Exhibits

Comment
Exhibit A to Application for the Appointment of Custodian

06/04/2021 Exhibits

Comment
Exhibits B through E to Application for the Appointment of Custodian

06/04/2021 Initial Appearance Fee Disclosure

Comment
Initial Appearance Fee Disclosure

06/04/2021 Summons Electronically Issued - Service Pending

Comment
Summons

06/08/2021 Clerk's Notice of Hearing

Comment
Notice of Hearing

06/08/2021 Ex Parte Motion

Comment
Ex Parte Motion for an Order Shortening Time

06/09/2021 Order Shortening Time

Comment
Order Shortening Time Re: Plaintiff's Motion for the Appointment of Alpharidge Capital

06/09/2021 Order Shortening Time

Comment
Order Shortening Time

06/09/2021 Notice of Entry of Order

Comment
Notice of Entry of Order Granting Motion to Shorten Time

06/16/2021 Affidavit of Service

Comment
Affidavit of Service

?
06/17/2021 Motion

Judicial Officer
Jones, David M

Hearing Time
9:00 AM

Result
Motion Granted

Comment
Petitioner's Application for the Appointment of Custodian

Parties Present
Petitioner

Attorney: Bauman, Frederick C

06/22/2021 Order

Comment
Order Granting Application for the Appointment of Alpharidge Capital LLC as Custodian of Entia Biosciences

06/22/2021 Notice of Entry of Order

Comment
Notice of Entry of Order Granting Application for the Appointment of Custodian

Nice Motion Granted

Alpharidge has been granted custo

I know. 11mm @ .06 is a sweet risk
If they can get it current.

I’m
Only looking at low floats with Sept 28, 3 months away..

ERGO:Wow.Another Super custo but nobody posting?Lol...

Yep! Someone trying to load size

SS is great. If something develops it could go hard.

Still getting loaded .. very interesting.

Waiting here something big coming imo

Very thin

Green is green

Down 30% on 45k yesterday - Can you say thin

Couldn’t agree more - for new comers below is the SS


ERGO SECURITY DETAILS
Share Structure

Market Cap Market Cap
919,644
12/02/2019
Authorized Shares
151,000,000
10/31/2019
Outstanding Shares
34,060,882
10/31/2019
Restricted
22,375,691
10/31/2019
Unrestricted
11,685,191
10/31/2019
Held at DTC
9,132,193
10/31/2019
Float
11,519,390
02/17/2017

SS Here is amazing

Snagged some more today

Nice DD...Something is up here imo... $ERGO








Shell Monster Stocks **Shell - Custodian - Material Event Plays** (SHELL)
https://investorshub.advfn.com/Shell-Monster-Stocks-**Shell-Custodian-Material-Event-Plays**-37363/

Another confirmation of NanoBiologics CEO and ERGO
Chief Scientific Officer working together.

https://investorshub.advfn.com/uimage/uploads/2019/11/30/weymu65456465454665.PNG

$ERGO Posting some interesting DD on ERGO. Odd Vol on Friday. Did some digging and came up with the following linkage. As you can see. Janelle has a past history with the Directors at ERGO. In addition, Marvin S. Hausman, M.D has links to Nanobiologics. Could be a merger coming.

Nanobiologics Website = https://www.nanobiologicscorp.com/


See Pics

https://investorshub.advfn.com/uimage/uploads/2019/11/30/fpclr5115156161566.PNG

https://investorshub.advfn.com/uimage/uploads/2019/11/30/ydaox546546546465.PNG

https://investorshub.advfn.com/uimage/uploads/2019/11/30/cpnrl446464644556.PNG

https://investorshub.advfn.com/uimage/uploads/2019/11/30/eddvh561516511516.PNG

Damn look at it go. Nice share structure. Did you get any?

Not that Ive found yet

Any reason?

ERGO volume

Cold fat fingers.

Will ERGO be taken over by PFNO? Or will PFNO be taken over by ERGO?Because PFNO is triple 3.

No doubt in my mind products Improve memory. I decided to try GlucoSano & ImmuSano mainly due to the potential of improving memory. After taking both of these on a daily basis, my thinking process speeded up & became clearer, and my ability to memorize improved. I don't understand why I don't see more posts from people who have tried these products especially knowing that there are other benefits also. In a way, I'm glad that there is not a lot of hype & questionable claims about these products, but I'm finally speaking out, because Nothing is being said (other than from the Company). As a stockholder, I want these products to succeed (of course), but as a happy customer, I also want to be able to buy them in the future.
Memorize

13:11 2/15/2012 ERGO Total Nutraceutical Solutions Common Stock ERGOD Entia Biosciences Inc. Common Stock 1-10 R/S **

Board Authorizes Corporate Restructuring for Shareholder Approval
STEVENSON, Wash., Nov. 7, 2011 (GLOBE NEWSWIRE) -- Total Nutraceutical Solutions, Inc. (TNS) (OTCBB:TNUS) announced today that its Board of Directors has unanimously agreed to seek shareholder approval at its upcoming Annual Shareholders Meeting in December to amend the Company's Articles of Incorporation as part of an overall strategy to expand the Company's biotechnology focus and better position and differentiate its growing portfolio of proprietary food-based solutions for the institutional and consumer markets. Once the proposed corporate actions are approved, the Company's name will change to Entia Biosciences, Inc. (ENTIA) and the existing TNS name will be transferred to a newly formed subsidiary that will concentrate exclusively on the sales and marketing of branded consumer products. ENTIA will focus on research & development of needed therapeutic dietary supplements, technology acquisition and licensing, and institutional sales of branded and private label solutions that are based on the Company's proprietary technology.

TNS started in 2008 as a consumer products company that developed and marketed mushroom-based supplements for animal and human consumption under its Sano™ brand. In 2010, the Company introduced its popular hair and nail growth supplement Groh™ that is now being sold online and through several of the country's leading salon chains. Two of the active ingredients in these products, Ergothioneine and Vitamin D2, are powerful antioxidants that the Company believes may additionally play an important role in reproductive health, stem cell preservation, neurodegenerative diseases such as multiple sclerosis, Parkinson's and Alzheimer's disease, as well as early aging. In 2011, the Company expanded into the institutional dietary supplementation market with its introduction of Ergo-D2™, an optimized blend of Ergothioneine and Vitamin D2, and the announcement of its first scientific study of the product with Massachusetts General Hospital to assess its efficacy as a potential dietary therapy or palliative therapy for Parkinson's disease patients. ENTIA intends to announce additional collaborative research studies and clinical trials in the coming months that will address other potential applications for the Company's proprietary food-based technology and products.

"Feedback from prospective customers and investors has been favorable for this next step in our corporate evolution," said Dr. Marvin S. Hausman M.D., Chief Executive Officer of TNS. "Institutions, as well as the general public, are looking for cost effective, scientifically proven solutions that can safely prevent or delay the progression of major diseases and enhance or replace existing therapies. The science of food-based biotechnology and personalized healthcare with natural products is in its infancy and ENTIA intends to become a technological leader within the institutional food sciences and supplementation markets. The use of "big-gun" costly chemical products with side effects to treat chronic disease is over-promoted and the public is most excited with the opportunity to try to prevent early stage diseases with natural food-based anti-inflammatory products."

About the Upcoming Annual Shareholders Meeting

Shareholders of record on November 4, 2011 will be entitled to vote in person or by proxy at the Company's Annual Shareholders Meeting expected to be held in Stevenson, Washington on December 19, 2011. The Company intends to file its preliminary form 14A proxy on November 11th and mail the final proxy by November 21st. In addition to approving the name change to Entia Biosciences, Inc. and transferring the TNS name to a new subsidiary, Shareholders will be asked to approve a 1:10 reverse split of the Company's common stock and the engagement of Peterson Sullivan LLC as the Company's auditors for 2012. A complete description of these matters will be disclosed in the final proxy statement distributed to Shareholders.

About Total Nutraceutical Solutions, Inc. and Entia Biosciences, Inc.

TNS is an emerging leader in whole food biotechnology that identifies, scientifically validates, and commercializes solutions that address multi-billion dollar markets for organic health, beauty and agriculture. The Company's growing portfolio of intellectual property includes extraction, enhancement, and uses for some of the most powerful antioxidants and bionutrients occurring in nature.

For more information, please visit our web sites at www.entiabio.com and www.totalnutraceutical.com

The Total Nutraceutical Solutions, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8060

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Total Nutraceutical Solutions (TNS), Inc. with the Securities and Exchange Commission. Further information on risks faced by TNS are detailed in the Form 10-K for the year ended December 31, 2010 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. TNS does not undertake any obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Visit TotalNutraceutical.com or contact the Company at 509-427-5132 info@totalnutraceutical.com.